A Phase II Trial to Assess the Safety and Immunogenicity of DNA Priming Administered by the ID Zetajet® With or Without ID Derma Vax™ Electroporation Followed by IM MVA Boosting in Healthy Volunteers in Tanzania and Mozambique

Inclusion Criteria: * Willing to undergo counselling and HIV testing. * Have a negative antigen/antibody ELISA for HIV infection. * Able to give informed consent. * Basic abilities to read and write. * Satisfactory completion of an assessment of understanding prior to enrolment defined as 90% correct answers after three opportunities to take test. * Resident of the region where the study is taking place. * At low risk of HIV infection. * Verbal assurances for adequate birth control measures. * Healthy as evidenced by clinical and laboratory measures Exclusion Criteria: * At risk of HIV infection. * Active tuberculosis. * A history of immunodeficiency, ongoing medical and/or psychiatric condition and/or chronic illness requiring continuous or frequent medical intervention. * Autoimmune disease. * Hives and severe eczema. * Substance abuse problems. * History of grand-mal epilepsy. * Received blood or blood products or immunoglobulins in the past 3 months. * Receiving immunosuppressive therapy such as systemic corticosteroids or cancer chemotherapy. * Use of experimental therapeutic agents within 30 days of study entry. * History of cardiac disease